Compare American Electric Power Company Inc (AEP) vs Amphastar Pharmaceuticals Inc (AMPH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American Electric Power Company Inc vs Amphastar Pharmaceuticals Inc — how do they compare? American Electric Power Company Inc trades at $137.22 (market cap $74.83B), while Amphastar Pharmaceuticals Inc trades at $18.71 (market cap $885.83M). The key difference: American Electric Power Company Inc is far larger — about 84.5× Amphastar Pharmaceuticals Inc's market cap, and American Electric Power Company Inc pays a 2.76% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AEP | AMPH | |
|---|---|---|
Market Cap | $74.83B | $885.83M |
Sector | Utilities | Health |
52-Week High | $138.69 | $30.81 |
52-Week Low | $103.96 | $16.87 |
Enterprise Value | $126.09B | $1.28B |
Dividend Yield | 2.76% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEP trades at $137.53, down 0.71% on the day, with strong analyst support (64% buy ratings) and a $142.82 consensus price target. The stock shows bullish technical momentum with recent earnings beats and robust revenue growth, climbing from $19.7B in 2024 to $21.9B in 2025. AEP benefits from AI-driven electricity demand and a $78B capital plan for grid expansion.
Outlook remains positive given AEP's strategic positioning in energy infrastructure, though risks include high capital expenditures and debt levels. The current valuation at 20.12x P/E appears reasonable for a utility with stable earnings growth and dividend payments, supporting a constructive view for long-term investors.
AMPH trades at $19.61, down 0.15% with a bearish technical outlook. The stock shows mixed fundamentals with a P/E of 11.81 and net margin of 11%, but recent earnings misses and declining 2026 profit projections raise concerns. Recent news includes a Zacks Strong Sell rating and a securities law investigation, while management focuses on transitioning to proprietary drugs for growth.
The outlook remains cautious with analyst consensus at Hold (66.7%) and a $20.40 price target offering limited upside. Key risks include earnings volatility, competitive pressures, and legal scrutiny. The stock presents moderate value but requires careful monitoring of execution on growth initiatives and upcoming Q2 earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Electric Power Company Inc
American Electric Power is one of the largest regulated utilities in the United States, providing electricity generation, transmission, and distribution to more than 5 million customers in 11 states. About 43% of AEP's of capacity is coal, with the remainder from a mix of natural gas (27%), renewable energy and hydro (19%), nuclear (7%), and demand response (4%). Vertically integrated utilities, transmission and distribution, and generation and marketing support earnings.
Read more on AEP →About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →
